Today GRAIL announced a favorable vote from an FDA Advisory Committee for the approval of the Premarket Approval application of the Galleri multi-cancer early detection test (MCED). The Committee considered Galleri’s safety, effectiveness, and overall benefit-risk profile for screening for the early detection of multiple types of cancer in adults aged 50 years and older. Read more: bit.ly/4rpmwUd #MCED #Galleri #CancerScreening

Full cohort results from GRAIL’s PATHFINDER 2 study have been published in @NatureMedicine, adding to the growing body of evidence supporting multi-cancer early detection (MCED) testing. Learn more: bit.ly/4y3psIK Rx Only. See Important Safety Information: bit.ly/411L6zk

Detailed peer-reviewed results from the NHS-Galleri trial are now published in @NEJM and @NatureMedicine, providing clinical utility and performance data. These results reflect GRAIL’s commitment to setting a high bar for MCED evidence—rigorously demonstrating Galleri’s potential to reduce late-stage diagnoses and find more cancers earlier. #EarlyCancerDetection #CancerScreening #MCED Learn more: New England Journal of Medicine: bit.ly/3Vbd5f8 Nature Medicine: bit.ly/4y9il1j Rx Only. See Important Safety Information: bit.ly/411L6zk

Greetings from Sunnyvale, California ☀️— GRAIL’s new HQ! We’re excited for this new chapter as we continue to work toward our mission to detect cancer early, when it can be cured.

Today GRAIL announced that the U.S. Food and Drug Administration’s (FDA) Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to meet on Sept. 23, 2026 to review the Premarket Approval (PMA) application for the Galleri® multi-cancer early detection (MCED) blood test. Learn more: bit.ly/4hV1Lgs

Today GRAIL reported second quarter 2026 financial results. Read the press release: bit.ly/4pZIRXX

We will announce second quarter 2026 financial results on August 5. Register for the webcast: bit.ly/3RoDKUq Read more: bit.ly/4pJMG3g

Today announced a collaboration with Priority Health, a nationally recognized nonprofit health plan and the third largest provider-sponsored health plan in the nation to make GRAIL’s Galleri multi-cancer early detection (MCED) test available to Priority Health’s self-insured employer groups. Learn more: bit.ly/3TklThO #MCED #EarlyCancerDetection

Many cancers stay hidden until it is too late. When cancer is diagnosed after it has spread distantly, it is more difficult to treat and typically has worse outcomes. Diagnosing cancer before Stage IV can make a meaningful difference. For a growing number of cancers, treatment with curative intent may still be possible at Stage III. That’s why reducing Stage IV diagnoses remains such an important part of improving cancer outcomes. Learn more: grail.com #CancerScreening #EarlyCancerDetection

Today GRAIL announced the closing of its previously announced equity financing with Samsung affiliates including Samsung C&T Corporation. Learn more: bit.ly/3StlF7I

Melissa didn’t take a multi-cancer early detection (MCED) test once and leave it at that. She made MCED testing part of her annual health routine. The first year, the test did not detect a cancer signal. The second year, she received a Cancer Signal Detected result with a predicted origin of liver/bile ducts. Melissa felt healthy and had no symptoms. Follow up diagnostic testing confirmed Stage I bile duct cancer. Now she’s using her story to encourage others to keep cancer screening part of the conversation, year after year. #CancerScreening #EarlyCancerDetection #MCED The overall sensitivity in study participants with liver/bile duct cancer was 93.5% (100% for stage I, 70.0% stage II, 100% stage III, 100% stage IV). Rx only. See Important Safety Information: galleri.com/safety-informati…

“Early detection can save an awful lot of lives, I think I’m evidence of that.” Ann joined the NHS-Galleri trial evaluating a multi-cancer early detection (MCED) test hoping her participation might help others. She never imagined it would help her, too. Watch her story and learn more about the NHS-Galleri trial: bit.ly/4wY05Ij The overall sensitivity in study participants with colon/rectum cancer was 82% (43.3% for stage I, 85% stage II, 87.9% stage III, 95.3% stage IV).

Robert signed on for the NHS-Galleri trial with the intention of advancing cancer research. When the multi-cancer early detection (MCED) test returned a Cancer Signal Detected result, he was shocked. On the latest episode of The Cancer SIGNAL podcast, host Rayshawnda Madison speaks with Robert as he shares how his follow-up journey eventually led to an early HPV-related cancer diagnosis, what it was like to navigate treatment and recovery, and how the experience changed the way he thinks about health and early detection. The Cancer SIGNAL is available wherever you listen to podcasts. #EarlyCancerDetection #MCED #Podcast Apple Podcasts: bit.ly/4byN5jM Spotify: bit.ly/4bOp9I4 Transcripts & more episodes: grail.com/podcast/

Dr. Nima Nabavizadeh, principal investigator for the PATHFINDER 2 study, shares key takeaways from this data. He noted: “As an oncologist, I have seen too many patients diagnosed only after their cancer has spread, when treatment decisions become more difficult. By helping find more cancers earlier, when more treatment options may be available, there is great potential for multi-cancer early detection to transform cancer screening.” Find all of GRAIL’s data from #ASCO26 here: bit.ly/4wY05Ij RX Only. See Important Safety Information: bit.ly/3QHmPWo

PATHFINDER 2 data being presented today at #ASCO26 offer new evidence on the safety and performance of a multi-cancer early detection (MCED) test when used alongside recommended #CancerScreenings. Review the results from the largest #MCED interventional study in North America: bit.ly/3QcmqBe RX Only. See Important Safety Information: bit.ly/3QHmPWo

When Doreen volunteered for the NHS-Galleri trial evaluating a multi-cancer early detection (#MCED) test, she never expected the study would identify a signal for #lymphoma in her own blood. Follow-up testing confirmed a Stage I-II lymphoma diagnosis and Doreen was able to promptly begin treatment. Today, she’s back on her bike and sharing her journey to help others understand the importance of #EarlyCancerDetection. See more about the NHS-Galleri trial: bit.ly/4wY05Ij #ASCO26 The overall sensitivity in study participants with lymphoma was 56.3% (27.3% for stage I, 58.3% stage II, 71.7% stage III, 60.9% stage IV).

Results from the NHS-Galleri trial presented at #ASCO26 found that the addition of the Galleri test to standard-of-care cancer screenings led to a four-fold increase in screen-detected cancers. Learn more about our data from ASCO: bit.ly/4wY05Ij The Galleri test does not detect a signal for all cancers, and false positive or false negative results can occur. RX Only. See Important Safety Information: bit.ly/3QHmPWo

Today at #ASCO26, we are presenting full results from the NHS-Galleri trial, evaluating annual multi-cancer early detection (MCED) blood testing in more than 142,000 participants across England’s National Health Service (NHS). Review the findings: bit.ly/4uBd80F RX Only. See Important Safety Information: bit.ly/3QHmPWo

Our #ASCO26 program highlights new data across #MCED testing, including detailed results from the NHS-Galleri trial, results from the PATHFINDER 2 study, and implementation insights in a private practice setting. See more: bit.ly/4nZhkF6 #EarlyCancerDetection

Want to stay up to date on all things GRAIL? Sign up for our newsletter to receive updates on the work we’re doing to shape the future of early cancer detection: bit.ly/44j6Jt6 #EarlyCancerDetection #CancerScreening #MCED